Last Updated : May 5, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Trosec | Trospium chloride | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
VFEND | Voriconazole | Candidemia | List with clinical criteria and/or conditions | Complete | ||
Pantoloc M | Pantoprazole magnesium | Gastric acid secretion, reduction of | List in a similar manner to other drugs in class | Complete | ||
Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
Trelstar | Triptorelin pamoate | Cancer, prostate | List in a similar manner to other drugs in class | Complete | ||
Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | List with clinical criteria and/or conditions | Complete | ||
Somavert | Pegvisomant | acromegaly | Do not list | Complete | ||
Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | ||
Aptivus | Tipranavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Caduet | Amlodipine besylate/ atorvastatin calcium | Hypertension/ Dyslipidemia | List with clinical criteria and/or conditions | Complete |